No immediate trading catalyst. Monitor IND filing for AT177 in H1 2027 and Phase 1a initiation in H2 2027 for pipeline progression signals.
Price Chart
Executive Summary
Adial Pharmaceuticals granted a new employee stock option to purchase 155,446 shares at $4.22 as an inducement for hiring. The filing is routine and contains no financial results, clinical data, or material corporate events — the stock option grant is administrative in nature.
Key Facts
- Inducement stock option for 155,446 shares at $4.22 exercise price (closing price on Sept 25, 2026).
- Option vests over four years (25% on first anniversary, remainder monthly).
- Grant made outside equity incentive plans under Nasdaq Listing Rule 5635(c)(4).
- Company acquired Azora Therapeutics in June 2026; lead program is AT177 (AhR agonist) for ulcerative colitis.
- IND filing for AT177 planned for H1 2027; Phase 1a SAD/MAD trial expected H2 2027.
Financial Impact
No financial impact — the option grant is a routine inducement award with no immediate cash or dilution effect beyond standard equity compensation.
Risk Factors
- AT177 is in IND-enabling studies; no clinical data yet — pipeline risk is high.
- Company is clinical-stage with no approved products; capital needs may require future financing.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3372449 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | EFFECT | $3.68 | awaiting T+60 | — | $3.68 (−0.00%) |
Oct 20, 2026 6d ago | 10-Q/A | $4.11 | awaiting T+60 | — | $3.68 (+10.46%) |
Oct 20, 2026 6d ago | S-3/A | $4.11 | awaiting T+60 | — | $3.68 (+10.46%) |
Oct 16, 2026 10d ago | DEFA14A | $3.62 | awaiting T+60 | — | $3.68 (−1.66%) |
Oct 16, 2026 10d ago | 8-K | $3.62 | awaiting T+60 | — | $3.68 (−1.66%) |
Sep 30, 2026 26d ago | Press Release | $4.13 | awaiting T+60 | — | $3.68 (−10.90%) |
Sep 18, 2026 5w ago | DEFA14A | $4.40 | awaiting T+60 | — | $3.68 (−16.36%) |
Sep 18, 2026 5w ago | 8-K | $4.40 | awaiting T+60 | — | $3.68 (−16.36%) |
Sep 16, 2026 5w ago | DEFA14A | $5.21 | awaiting T+60 | — | $3.68 (−29.37%) |
Sep 16, 2026 5w ago | 8-K | $5.21 | awaiting T+60 | — | $3.68 (−29.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers